{"url_path":"/sec/ispc/8-k/2026-06-01/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1558569/0001213900-26-063575-index.html","accession_number":"0001213900-26-063575","cik":"0001558569","ticker":"ISPC","issuer_name":"iSpecimen Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1558569/0001213900-26-063575-index.html","primary_entity_key":"0001558569","primary_entity_name":"iSpecimen Inc."},"word_count":328,"has_tables":true,"body_markdown":"** **\n\n****\n\n \n\n** **\n\n****\n\n \n\n \n\n** **\n\n**Item 3.01. Notice of Delisting or Failure to\nSatisfy a Continued Listing Rule or Standard; Transfer of Listing.**\n\n \n\nOn May 29, 2026, iSpecimen Inc. (the “Company”)\nreceived a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum\nof $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”).\n\n \n\nAs reported in the Company’s Quarterly Report\non Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May\n29, 2026, the Company does not meet the alternative continued listing standards under the Capital Market’s equity standard, market\nvalue of listed securities standard, or net income standard.\n\n \n\nThe Notice has no immediate effect on the listing\nor trading of the Company’s common stock, which will continue to trade on the Nasdaq Capital Market under the symbol “ISPC.”\nUnder Nasdaq’s rules, the Company has 45 calendar days from the date of the Notice to submit a plan to regain compliance. If Nasdaq\naccepts the Company’s plan, the Company may be granted an extension of up to 180 calendar days from the date of the Notice to evidence\ncompliance.\n\n \n\nThe Company intends to submit a compliance plan\nto Nasdaq within the required 45-day timeframe. There can be no assurance that Nasdaq will accept the Company’s plan or that the\nCompany will ultimately regain compliance within the applicable time period. If the Company’s plan is not accepted, the Company\nwill have the opportunity to appeal that decision to a Nasdaq Hearings Panel.\n\n \n\n1\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDated: June 1, 2026\n\n \n\n \niSPECIMEN INC.\n\n \n \n \n\n \nBy:\n/s/ Katharyn Field\n\n \n \nName:\nKatharyn Field\n\n \n \nTitle:\nChief Executive Officer\n\n \n\n2"}